Search Within

Advanced Practice Providers

  1. "Matthew Matasar"
Formats
  1. Meeting Abstract (26)
  2. Journal Article (11)
Groups
  1. Center for Hematologic Malignancies (37)
  2. Department of Medicine (37)
  3. Hematologic Malignancies, Division of (37)
  4. Lymphoma (37)
  5. Survivorship Research (37)
  6. Nursing (28)

More Groups

People
  1. Matthew Matasar (37)
  2. Andrew Zelenetz (32)
  3. Alison Moskowitz (27)
  4. Ariela Noy (26)
  5. Maria Palomba (26)
  6. Paul Hamlin (25)

More People

Years
  1. 2022 (3)
  2. 2021 (7)
  3. 2020 (2)
  4. 2019 (4)
  5. 2018 (3)
  6. 2017 (4)

More Years

Publications
  1. Blood (19)
  2. Journal of Clinical Oncology (5)
  3. Hematological Oncology (3)
  4. Annals of Oncology (2)
  5. American Journal of Hematology (1)
  6. British Journal of Haematology (1)

More Publications

Publishers
  1. American Society of Hematology (19)
  2. American Society of Clinical Oncology (5)
  3. Wiley Blackwell (3)
  4. Elsevier Inc. (2)
  5. Elsevier Science, Inc. (2)
  6. Oxford University Press (2)

More Publishers

Results (37)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase I/II trial of the combination of romidepsin and lenalidomide in patients with relapsed/refractory lymphoma and myeloma: Phase I results
    Meeting Abstract

    Lunning, M. A.; Ruan, J.; Nair, S.; Boruchov, A. M.; Byrne, R.; Gerecitano, J. F.; Hamlin, P. A.; Inserra, B.; Leonard, J.; Lynch, P.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Safety and early efficacy in an ongoing pilot study of brentuximab vedotin and AVD chemotherapy followed by 30 gray involved-site radiotherapy for newly diagnosed, early stage, unfavorable risk Hodgkin lymphoma
    Meeting Abstract

    Kumar, A.; Yahalom, J.; Schoder, H.; Caron, P.; Drullinsky, P.; Gerecitano, J. F.; Hamilton, A.; Hamlin, P.; Horwitz, S. M.; Jacob, A. G.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • FDG-PET adapted sequential therapy with brentuximab vedotin and augmented ICE followed by autologous stem cell transplant for relapsed and refractory Hodgkin lymphoma
    Meeting Abstract

    Moskowitz, A.; Schoder, H.; Gerecitano, J. F.; Hamlin, P.; Horwitz, S. M.; Matasar, M. J.; Keskinyan, V. S.; McCall, S.; Noy, A.; Palomba, M. L.; more...
    Blood (2013)

    Fulltext@MSK | Save
  • Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma
    Journal Article

    Moskowitz, A. J.; Hamlin, P. A. Jr; Perales, M. A.; Gerecitano, J.; Horwitz, S. M.; Matasar, M. J.; Noy, A.; Palomba, M. L.; Portlock, C. S.; Straus, D. J.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Risk-adapted therapy using biopsy confirmation of abnormal interim FDG-PET for patients with advanced stage diffuse large B cell lymphoma (DLBCL), and exploratory evaluation of FLT-PET
    Meeting Abstract

    Moskowitz, C. H.; Schoder, H.; Hamlin, P. A.; Gerecitano, J. F.; Horwitz, S. M.; Matasar, M. J.; Moskowitz, A. J.; Noy, A.; Palomba, M.; Portlock, C. S.; more...
    Annals of Oncology (2011)

    Fulltext@MSK | Save
  • Updated results of a phase II trial of bendamustine in relapsed and refractory Hodgkin lymphoma
    Meeting Abstract

    Moskowitz, A. J.; Hamlin, P.; Gerecitano, J.; Horwitz, S.; Matasar, M.; Noy, A.; Palomba, M. L.; Portlock, C.; Straus, D.; Graustein, T.; more...
    Annals of Oncology (2011)

    Fulltext@MSK | Save
  • High number of successful mobilizations associated with the use of plerixafor and colony stimulating factors in patients with multiple myeloma (MM) and lymphoma treated at Memorial Sloan-Kettering Cancer Center
    Meeting Abstract

    Adel, N. G.; Mathew, S.; Harnicar, S. J.; Mccullagh, E.; Landau, H.; Giralt, S.; Vanak, J.; Chimento, D.; Lucarelli, C.; Matasar, M. J.; more...
    Blood (2010)

    Fulltext@MSK | Save